Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07079397

Hyaluronic Acid Filler Migration

The Integration Pattern of Non-Animal Stabilized Hyaluronic Acid (NASHA)- and Optimum Balance Technology (OBT)-Based Fillers: An Ultrasound and Magnetic Resonance Imaging (MRI) Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Erevna Innovations Inc. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Soft tissue filler injections continue to grow in popularity as a method of facial rejuvenation, including volume restoration and contour enhancement. Many different hyaluronic acid (HA)-based fillers are available on the market and differ in terms of their physical and chemical properties, which results in families of fillers (e.g., Non-Animal Stabilized Hyaluronic Acid - NASHA vs. Optimal Balance Technology - OBT) with different tissue integration patterns. It has been proposed that the properties of fillers significantly influences their tendency to migrate. More specifically, thick fillers may be less prone to migration compared to fluid fillers. However, a detailed knowledge of facial anatomy, safer injection techniques, and careful product selection based on filler qualities may be preventive measures for filler migration. The goal of this study is to describe the short and intermediate-term product distribution/integration patterns of NASHA and OBT-based fillers, and to evaluate the evidence (if any) of filler migration from the intended site of injection.

Conditions

Interventions

TypeNameDescription
DEVICERestylane InjectablesParticipants will receive pan-facial treatment in at least one facial area using a Restylane NASHA product and at least one different facial area using Restylane OBT product. Participants will undergo three (3) scheduled MRI scans thoughout the duration of the study post HA injections.

Timeline

Start date
2025-12-11
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2025-07-23
Last updated
2026-01-22

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT07079397. Inclusion in this directory is not an endorsement.